Walder Wyss advised Alentis Therapeutics AG on the deal.
Alentis Therapeutics AG announced a USD 67m series B financing round.
Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital.
Alentis Therapeutics AG is a Swiss biotech developing breakthrough treatments for fibrotic diseases.
Proceeds from the financing will be used will be used primarily for proof-of-concept clinical trials of Alentis’ first-in-class, Claudin-1 targeting, anti-fibrotic molecules in advanced liver and kidney fibrosis, and support ongoing drug discovery programs targeting other fibrotic diseases and hepatobiliary cancers.
The Walder Wyss team was led by Alexander Gutmans (Picture – Partner, Corporate/M&A and Venture Capital) and included Markus R. Frick (Partner, IP/IT), Manuel Bigler (Senior Associate IP/IT), Jessica Aeschbach Flórez (Senior Associate, Corporate/M&A and Notarial Services), Karina Tschon (Associate, Corporate/M&A and Venture Capital) and Michelle Bruni (Associate, Tax).
Involved fees earner: Jessica Aeschbach Flórez – Walder Wyss Ltd.; Manuel Bigler – Walder Wyss Ltd.; Michelle Bruni – Walder Wyss Ltd.; Markus Frick – Walder Wyss Ltd.; Alexander Gutmans – Walder Wyss Ltd.; Karina Tschon – Walder Wyss Ltd.;
Law Firms: Walder Wyss Ltd.;
Clients: ALENTIS Therapeutics;